Amgen Faces Data Breach Affecting Patient Information
Amgen has experienced a data breach affecting its third-party operated cloud-based systems, resulting in the exposure of proprietary company data and private patient health information. The incident was disclosed via an 8-K filing with the SEC, where Amgen stated it had activated its cybersecurity response plan to contain the leak. While no immediate impact on products, manufacturing or financial reporting has been observed, investigations are ongoing. This breach occurs amid regulatory scrutiny over Tavneos (avacopan), a drug generating $459 million in 2025 and now under review for potential approval revocation due to concerns about clinical data integrity. The New England Journal of Medicine retracted the pivotal paper supporting its initial approval earlier this year. Amgen is also dealing with broader cybersecurity challenges within the life sciences sector, as other companies like Stryker, Abbott Laboratories, and Novo Nordisk have faced similar attacks recently.
Topics: cybersecurity patient_data_exposure third-party_risk